1-3 of 3
Fadoua El Moustaid
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Travel Burden and Travel Costs of Bispecific Antibodies in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Relapsed/Refractory Follicular Lymphoma

Scott F Huntington, Anthony Masaquel, Esprit Ma, Eric Zuk, Hélène Parisé, Matthew Davis, David Fox, Fadoua El Moustaid, Arliene Mangalindan, Lourenia Cassoli, Mei Wu, Zachary AK Frosch
Journal: Blood
Blood (2024) 144 (Supplement 1): 782.
https://doi.org/10.1182/blood-2024-198414
Published: 2024
Journal Articles

An Economic Analysis Assessing the Budget Impact of Introducing Glofitamab with Gemcitabine and Oxaliplatin for Autologous Stem Cell Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma to a United States Health Plan

David Fox, Katherine L Rosettie, Fadoua El Moustaid, Anthony Masaquel, Lourenia Cassoli, Christopher R. Flowers
Journal: Blood
Blood (2024) 144 (Supplement 1): 3646.
https://doi.org/10.1182/blood-2024-198451
Published: 2024
Journal Articles

Glofitamab with Gemcitabine and Oxaliplatin Is Cost-Effective Versus Rituximab with Gemcitabine and Oxaliplatin for US Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Who Were Not Candidates for Autologous Stem Cell Transplant

David Fox, Fadoua El Moustaid, Anthony Masaquel, Katherine L Rosettie, Hazal Celik, Lourenia Cassoli, Christopher R. Flowers
Journal: Blood
Blood (2024) 144 (Supplement 1): 5027.
https://doi.org/10.1182/blood-2024-198461
Published: 2024